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change is one example ofthe United States'
flawed approach toward weaving scientific
prediction into policy. "The idea is that a
scientific answer-[for instance,] a global
warming prediction-can be found, and
then policy makers can apply rules to deal
with it." A better tactic, Sarewitz said, is to
recognize up front that scientists may never
know enough to predict global warming
accurately. They might do more good team-
ing up with policy makers and everyday citi-
zens to find alternatives to prediction such as
flexible strategies that mayhelp a given com-
munity confront the range of global warm-
ing possibilities. "The instinct is to predict,"
Sarewitz said. "But the promise ofprediction
just isn'talways met."
In such cases, age-old adages such as
"better safe than sorry," "first, do no
harm," and "look before you leap" may
come into play. The transformation ofsuch
adages, however, into an emerging environ-
mental philosophy caused great debate at
the meeting. Scientists explained the theory
behind and possible uses of the so-called
"precautionary principle," which holds that
industry and governments should prevent
pollution, technology, or other activities
that have even the potential to harm
human or environmental health.
The controversy lies in the fact that
some scientists suggest society should go as
far as stopping a new technology or pollut-
ing activity in its tracks when it appears
that it might harm others-even if scien-
tists can't actually prove that it does. While
this idea has crept into a few pollution laws
in Germany and the United Kingdom, it's
a far cry from environmental policy in the
United States, which relies on techniques
such as risk assessment and cost-benefit
analysis to weigh the pros and cons of a
polluting activity. Toxicologists at the
meeting pressed the scientific panel to
explain how they could base sound envi-
ronmental policy on a philosophy that
doesn't require scientific certainty about a
substance's toxicity. Steve Breyman, a polit-
ical scientist at Rensselaer Polytechnic
Institute in Troy, New York, countered
that he and others want to "err on the side
ofhuman health," and that there are many
examples, such as lead poisoning and smok-
ing, of how people's health suffered while
scientists debated risk.
Ken Geiser, director of the Toxics Use
Reduction Institute at the University of
Massachusetts in Lowell, described several
relatively easy ways to put the precaution-
ary principle into play, such as replacing
potentially toxic chemicals with more neu-
tral substitutes, recycling materials, and tin-
kering with production processes to pro-
duce less pollution. For the past decade, the
institute has been advising Massachusetts
companies how to do these things without
hurting profits or productivity. Geiser and
his colleagues advocate "clean production,"
a style ofmanufacturing that cuts pollution
to minimal levels. This kind of approach,
Geiser argued, is a feasible way to a more
sustainable society.
The primary push for the precautionary
principle comes from the Science and
Environmental Health Network, a national
nonprofit organization of scientists and
environmentalists. It remains to be seen
whether the U.S. Environmental Protection
Agency or other federal government agen-
cies will ever formally adopt the principle,
Breyman said. He suggested, however, that
increasing disease and ecosystem damage
may bring precaution foremost in the
public's mind.
Tracking Risk
When the cluster of children's leukemia
cases featured in the recent movie A Civil
Action surfaced in Woburn, Massachusetts,
in the mid-1980s, state epidemiologists
weren't even tracking cancer cases.
Scientific scrutiny ofthe interplay between
genes and the environment has come a long
way since then. But panelists at the annual
meeting of the American Association for
the Advancement of Science, held in
Anaheim, California, in January 1999,
posed the question that now presents itself
to researchers crossing traditional discipli-
nary boundaries: how to decipher ever-larg-
er amounts ofcomplex data.
"We've gone about as far as we can go
independently with the two sciences that
feed public health, toxicology and epidemi-
ology," said panelist Christopher
Schonwalder, the NIEHS director ofinter-
national programs. "Now is the time to
bring them together ifour understanding is
to advance," he said.
Combining cancer registries and right-
to-know laws, for example, boosts the study
of environmental hazards, said Sandra
Steingraber, an ecologist with the Women's
Community Cancer Project and author of
Living Downstream. `Thanks to activism, a
pipeline is being built between the two
giant databases," she said.
Investigators have recognized the futili-
ty oftracking the risk from specific etiolog-
ic agents, pointed out Devra Lee Davis of
the World Resources Institute, "because
disease patterns will always reflect mixed
environmental hazards." Similarly, expo-
sure patterns are used more to provide
warnings about potential hazards than to
forecast disease outcomes. "Exposure occurs
to a finite number ofmaterials," Davis said.
"Health is afunction ofmanyvariables."
Studying genes or the environment
independently, panelists said, is giving way
to studying the interactions that cause
human disease. Yet, according to Columbia
University researcher Ruth Ottman, "There
has been surprisingly little work to date on
what that interaction is, how to detect it,
and what kinds ofstudy designs should be
used to look at these questions."
Modelers face challenges on both
fronts. Efforts to develop models to
describe the risk of exposure from single
agents have been frustrated, reported Oak
Ridge National Laboratory researcher
Troyce Jones. The carcinogenic mecha-
nisms are simply too complex, and the
immune system too variable. "In spite ofall
the knowledge at this meeting and all the
knowledge in the published literature, we
can barely, barely get past 'go' going either
direction-backwards from disease to expo-
sure, or from exposure to disease," Jones
said. As researchers continue to shift from
answering the question ofwhat a dose is to
what a dose does, he said, better risk assess-
ment and policy can be formulated.
Specifically, he said, analysis of databases
derived from considerations ofreactive oxy-
gen can generate direct indices of how the
immune system is modulated by different
environmental variables.
Joellen Lewtas, a toxicological chemist
with the U.S. Environmental Protection
Agency, reported success with using bio-
markers in her work in the Czech Republic
to look at the progression from exposure to
what ultimately could be increased cancer
risk. DNA adduct measurements from the
study, in particular, offer some opportunity
to combine epidemiological data with toxi-
cological data, Lewtas explained. Such mea-
surements reflect not only exposure,
absorption, and transport but also metabo-
lism, DNA repair, and cell turnover.
"Biomarkers can provide very specific evi-
dence of exposure and confounding expo-
sures," Lewtas explained. "They can be
used to evaluate molecular dose and dam-
age related either to health outcomes or ...
to the exposure biomarkers, which in turn
provide the basis for studying susceptible
subpopulations."
Researchers attempting to interpret data
on disease susceptibility genes face equally
complex problems. "For the most part, we
have a hard time explaining the effect of
one gene polymorphism in relationship to
an exposure," said NIEHS researcher
Douglas Bell.
Although researchers working with the
Environmental Genome Project and similar
projects have identified roughly 60,000
variants among disease susceptibility genes
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and hundreds ofvariants in specific genes
involved in environmental exposures, deci-
phering the data is where things get tricky.
"As we layer on hundreds and thousands of
variations, I suspect it will be a very diffi-
cult task for the epidemiologists, statisti-
cians, geneticists, and biochemists who try
to explain exactlywhat's going on at a bio-
logical level," Bell said. "In reality, there
may be many alternative pathways at each
step in the exposure-disease path and we
really don't know how to model or even
thinkabout these systems at this point."
Understanding the interaction between
genes and environment enables scientists to
have greater accuracy and precision in the
measurement and detection ofboth genetic
and environmental effects, said Ottman.
She offered a series of epidemiological
models of interaction at the meeting and
remains confident that as more genes that
affect disease risk continue to be identified,
testing of interaction models will become
more feasible; the next step is disease pre-
vention.
Despite exciting emerging perspectives
on exposure, interactions, and risk, for
now, said Schonwalder, "we don't know a
lot, but one thingwe can sayforsure is that
we're not getting it right. We're spending
billions ofdollars to control chemicals and
we don't know which ones are really haz-
ardous and which are not. We're either
overcontrolling, which means we're spend-
ing a lot of money in the economy that
doesn't need to be spent, or we're under-
controlling, in which case we're causing a
lot of human suffering and disease and
we're spending an awful lotonhealth care."
Finally, Schonwalder said, "The returns on
investment in research toward understand-
ingdisease cause and effect can behuge."
understanding howAAV enters cells, scien-
tists will have more information for decid-
ing how and when to use the virus for
effective human gene therapy.
Gene therapy works by using a geneti-
cally altered vector to convey replacement
genes to diseased cells. AAV is commonly
used for this purpose because it can infect
several different kinds of cells (unlike, for
example, the AIDS virus, which attacks
only a specific type ofwhite blood cell). It
is also nonpathogenic, so practitioners
don't have to worry about the vector caus-
ing adverse health effects in their patients.
AAV is currently used in gene therapies for
cystic fibrosis, Parkinson's disease, and
hemophilia, amongother conditions.
Integrins occur in various combinations
of 1 of 16 different alpha subunits and 1 of
8 different beta subunits. Understanding
the role that the aVO5 integrin plays in
AAV uptake will allow researchers flexibili-
ty in exploiting its properties, depending
on the needs of the disease being treated.
For instance, they could upregulate the
receptor (or increase its numbers on the cell
surface) to enhance uptake.
The UNC research team built upon
earlier studies that showed that adenovirus
interacts with axV integrins to facilitate
internalization ofthevirus. Adenovirus uses
two different receptors to mediate viral
infection. The first receptor attaches wan-
dering viruses to the cell surface, and the
second receptor, the aVfi5 integrin, actual-
ly "pulls" the virus inside the cell. Because
AAV coevolved with adenovirus, the UNC
team thought that the two viruses might
share one of the same receptors. In fact,
they found that they share the secondary
receptor but not thefirst.
The team compared hamster cell lines
that either lacked aVP5 or specifically
A New Window on
a Molecular
Doorway
Research published in the
January 1999 issue ofNature
Medicine may help scientists
make a good thing-gene
therapy-even better.
Investigators at the Uni-
versity of North Carolina at
Chapel Hill (UNC) have
found that the presence of
aVj5 integrins (a certain
type of receptor protein) on
cell surfaces makes it easier
for those cells to be infected
with adeno-associated virus
(AAV), a commonly used
gene therapyvector, or deliv-







The key to infection? Identification of the aVI5 integrin as a secondary
receptor for adeno-associated virus (AAV) offers evidence of how viruses
infect cells, and may provide gristfor new genetherapies.
expressed aVfi5. The cells were exposed to
recombinant forms of adenovirus and
AAV. They found that infection rates of
the aV,B5-positive cells were 260% higher
for AAV (and 320% higher for adenovirus)
than in the cells that lacked the aV,5 inte-
grin. To determine whether, and to what
extent, aVP5 speeds AAV entry into a cell,
the scientists applied a strain of the virus
tagged with fluorescent dye to the two cell
lines. The aV[5-positive line was found to
internalize the virus at a much faster rate
(within 10 minutes) than the aVP5-defi-
cient line (which took up to 60 minutes).
Candace M. Summerford, a graduate stu-
dent at the Gene Therapy Center at UNC
who led the study, says, "We're lookingat a
phenomenon that facilitates viral entry but
isn't absolutely necessary." However, she
continues, "How fast the virus can get into
the cell may define the odds of infection."
Summerford's team is currently investigat-
ing the use ofAAV as a vector for anti-
cancerstrategies.
According to R. Jude Samulski, direc-
tor ofthe Gene Therapy Center, AAV is a
defective parvovirus, meaning it is unable
to complete its life cycle on its own. It
needs the assistance ofa "helper" cell such
as adenovirus or, as was more recently dis-
covered, herpesvirus. Because AAV can
coexist with at least two different helper
viruses, it may have multiple avenues of
entry into a cell; that is, it may have access
to the sum ofthe different cells targeted by
its helper cells. Identification of the viral
receptors for AAV has helped researchers
understand the broad access to cells ofthis
virus. It is this "tropism" of AAV that
makes the virus a good choice for a gene
therapy vector, because it can be used to
transport replacement proteins into several
different environments. making it a sort of
all-terrain vehicle ofgene therapy.
E A better understanding of how
ci AAV enters cells may also help scien-
C. tists understand the more pathogenic
to strains ofparvovirus, such as the B19
E strain, which causes erythema infectio-
sum ("fifth disease") in humans. This
disease is symptomized by a rash, low-
grade fever, fatigue, joint pain, and
swelling. B19 infection can be danger-
ous for patients with blood disorders
such as sickle cell anemia and hemo-
philia. In pregnant mothers, infection
with the B19 strain can result in spon-
taneous abortion.
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